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New Dosing Recommendations for Safe Use of 
Colistin 
Bilal Ahmad: Drug Information Pharmacist 
 
Following are the new dosing recommendations for safe use of Colistin was 
endorsed by the American College of Clinical Pharmacy (ACCP), European 
Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious 
Diseases Society of America (IDSA), International Society for Anti-infective 
Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society 
of Infectious Diseases Pharmacists (SIDP) . 
 
In normal renal function patient, loading dose remains same (~9 million IU), 
however initiation of maintenance dose have a range of 12-24 hours later. 
Maintenance dose frequency has been changed from three times to two daily at 
12 hour interval. 
 
In AKI, for severe infections deep seated infection dose shouldn’t be decreased 
from renal adjusted dose, if otherwise needed switch to less nephrotoxic agent. 
 
Reference: 
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American 
College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious 
Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti- 
infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious 
Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 Jan;39(1):10-39. doi: 10.1002/phar.2209. 
   
 
Fournier’s Gangrene reported with SGLT2 
Inhibitors for Diabetes 
Noor us Saba, Trainee pharmacist 
 
A rare but serious infection have been reported with the use of Sodium-glucose 
cotransporter-2 (SGLT2) inhibitors, Antidiabetic Type II Drug, This serious 
rare infection, called necrotizing fasciitis of the perineum, is also referred to 
as Fournier’s gangrene that develop within months of patients starting SGLT2 
inhibitors. 12 cases have been reported since 2013. Currently two SGLT2 
inhibitors Dapagliflozin and Empagliflozin are available in Pakistan. 
 
Reference 
Drug Safety Communications. US Food and Drug Administration Web site. https://www.fda.gov/drugs/ 
drugsafety/ucm617360.htm. Accessed March 10, 2019 
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Drug Use: The Three Dosage form of Fosfomycin 
Sheda Muhammad, Pharmacist, In Patient Pharmacy Services 
 
Fosfomycin is currently available in 3 different formulations 
Oral Sachet: Fosfomycin trometamine is available as a 3 gram sachet for oral use and is used as single dose sachet 
for the treatment of uncomplicated UTIs and 3 gm q72h for a total of 3 doses for complicated UTIs especially in 
males. In children less than 15 years and greater than 1 year, 2 gram may be used safely while in children less than 1 
year 1 gram fosfomycin trometamol may be used for complicated and uncomplicated UTIs. Following a single 3-g 
dose of fosfomycin trometamol, peak urine concentrations are reached within 4h. High urine as well as bladder tissue 
concentrations ( 128 mg/liter) are retained for 1 to 2 days, which is sufficient to eliminate the majority of common 
uropathogens. 
Oral Capsule Form: Fosfomycin calcium is available as 500 mg capsule and also as suspension 250 mg/5ml for 
pediatric use. Capsules can be used as 1000 mg every 8 hourly for 7 days for uncomplicated UTIs in adults while 50 to 
100 mg/kg/day in 3 to 4 divided doses in children less than 1 year and 100 to 200 mg per kg per day in children more 
than 1 year. 
Parenteral Form: Fosfomycin disodium is available as parenteral therapy and its dosage is range from a 12- to 16-g 
per day, administered in 2 to 4 divided doses. For serious infections like meningitis 8 g every 8 hourly may be used. In 
children and neonates following dosages may be used. 
Premature neonates (age <40 weeks) = 100 mg/kg/day IV (divided q12h) 
Neonates(age 40-44 weeks) = 200 mg/kg/day IV (divided q8h) 
Infants 1-12 months (wt up to 10 kg) = 200-300 mg/kg/day IV (divided q8h) 
Age 1-12 years (wt 10-40 kg) = 200-400 mg/kg/day IV (divided q6-8h) 
 
References: 
The Sanford Guide to antimicrobial therapy (digital version) 
 
 
Losartan, An Effective Alternative Approach in Managing Marfan 
Syndrome 
Haleema Noor, IPD Pharmacist 
 
American College of Cardiology/American Heart Association (ACC/AHA) guidelines suggest use of β blockers 
prophylactically in Marfan Syndrome (MF). Recent studies doesn’t favor the use of β blockers because of its indefinite 
mechanism of action and associated side effects on long term use including bradyarrythmia, bronchospasm in patients 
with COPD, mood disturbance and other complications in diabetic patients.[1] Losartan minimizes the TGF- β 
(transforming growth factor beta 1) expressions, which is associated with fibrosis, thereby reducing damage caused by 
matrix degradation in the aortic wall. Additionally, ARBs has a better side effect profile. Due to these mechanisms, it can 
be considered alternative therapy for the syndrome. [2] Proposed recommended dose for 6 months to 25 years 0.4-1.4 
mg/kg/day not exceeding a total of 100mg/day as approved by FDA for treatment of hypertension. [2] 
 
Reference 
1. Bin Mahmood SU, Velasquez CA, Zafar MA, et al. Medical management of aortic disease in Marfan syndrome. Ann Cardiothorac Surg. 2017;6(6):654-661. 
2. Sartor L, Forteza A. Strategies to prevent aortic complications in Marfan syndrome. J Thorac Dis. 2017;9(Suppl 6):S434-S438. 
 
Pharmacy Newsletter 3 
 
 
Pediatric Dose Calculation when no Pediatric Dose Available. 
Nosheen Anwer, Clinical pharmacist, 
 
Current situations regarding selection of pediatric doses do not guarantee safe and effective dose recommendation 
in pediatric population. Calculation of adult doses according to age, body surface area, weight and other co variants 
deprived of supportive data as well as evidences leads to unsafe practice, when a health care provider estimates 
pediatric dose from it. Implication of such practice remains unquestioned. As pediatric developmental pattern affects 
pharmacokinetics and exposure - response relationships so use of such experimental approaches are not highly justified. 
Pediatric population has nonlinear pharmacokinetics at different ages, Quantitative methodology advancements 
analyzing clinical pharmacological data offer prescribers, pharmacist, and researchers an appropriate tool for estimating 
which dose is appropriate for pediatric population. Functional Scaling also suggest an effective way (1, 2, 3) to relate 
dose calculation with weight via non-linear relationship for example allometric scaling; 
 
P child = P adult. (Wt /70)* 
(P= parameter of interest, * allometric exponent) 
 
Refining pharmacological models can lead to safe prediction of pediatric dosing and state of art approach. Still further 
research is needed in this important aspect of safe medication usage. 
 
References: 
1 Prediction of drug clearance in children: impact of allometric exponents, body weight, and age, Mahmood I, Ther Drug Monit. 2007 Jun; 29(3):271-8. 
2 Prediction of drug clearance in children from adults: a comparison of several allometric methods, Mahmood I, Br J Clinical Pharmacological. 2006 May; 61(5) 
3 Review Mechanism-based concepts of size and maturity in pharmacokinetics. Anderson BJ, Holford NH, Annu Rev Pharmacology Toxicology. 2008; 48():303-32 
 
Drug Safety in G6PD | An Updated List. 
 
DRUG RISK FOR WHOM 
Arginine* Low All 
Ascorbic acid* High All 
Brinzolamide* High All 
Bupivacaine* High All 
Chloramphenicol* High Medit, Asian 
Chloroquine* High Medit, Asian 
Chloroquine + proguanil* High Medit, Asian 
Ciprofloxacin* High All 
Dapsone (diphenylsulfone)* High All 
Diethylamine High All 
Dimenidrinato (Dimenhydrinate)* High All 
Dimercaprol* High All 
Diphenylhydramine (difenilhydramine)* Low All 
Dopamine* Low All 
Dorzolamide* High All 
Doxurubicin* High Medit, Asian 
Enoxacin* High All 
Epirubicin* Low All 
Glibenclamide* High Medit, Asian 
Gliclazide* High All 
Glimepiride* High All 
Glipizide* High All 
Glucosulfone (glucosulfone sodium) High All 
Hydroxychloroquine* High All 
Isobutyl nitrite High Medit, Asian 
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Isoniazide* Low All 
Levodopa* Low All 
Levofloxacin* High Medit, Asian 
Lomefloxacin High All 
Mefloquine* High All 
Menadiol sodium sulphate (vitamin K sodium sulphate) High All 
Menadione (Menaphthone)* High All 
Menadione sodium bisulfite High All 
Mesalazine -5-amino-salicylic acid* High Medit, Asian 
Metamizole High Medit, Asian 
Methyltioninium chloride (Methylene blue)* High All 
Morphine* Low All 
Moxifloxacin* High Medit, Asian 
Nalidixic acid* High Medit, Asian 
Naphtalene (Pure naphtaline) High All 
Nitric oxide High All 
Nitrofurantoin* High All 
Nitroglycerine* High All 
O-Acetyl salicylic acid (Acetylsalicylic acid)* High Medit, Asian 
Ofloxacin* High Medit, Asian 
Oxidase (Urate oxidase) High Medit, Asian 
Pramaquine High All 
Paracetamol (acetaminophen)* Low All 
Phenazopyridine* High Medit, Asian 
Phenytoin* Low All 
Phytomenadione (vitamin K1)* Low All 
Pipemedic acid High All 
Primaquine* High Low 
Probenecid High All 
Procainamide* Low All 
Propylene glycol Low All 
Quinidine* High All 
Quinidine + phenylhydrazine High All 
Quinidine + quinine Low All 
Sodium nitroprusside* High All 
Streptomycin* Low All 
Sulfacetamide* High All 
Sulfadiazine* Low All 
Sulfadiazine + trimethoprim* Low All 
Sulfadiamidine High All 
Sulfamethoxazole High All 
Sulfanilamide High All 
Sulfapyridine High All 
Sulfasalazine* High All 
Trimethoprim + sulfamethoxazole* High All 
Trinitrotoluene* High Medit, Asian 
*Formulary Medicines 
Reference: 
https://www.g6pd.org/en/Home.aspx 
 
Provide us your Valuable Feedback! 
To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful 
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an 
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu 
Thank you in advance for your feedback! 
Link: 
https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2 
     The Aga Khan University Hospital, Karachi 
